Impact of istradefylline on the adjustment of levodopa dose escalation in Parkinson’s disease: Results of the ISTRA ADJUST PD randomized, controlled study
Objective: To evaluate the effect of istradefylline (IST), an adenosine A2A receptor antagonist, on the adjustment of levodopa dose escalation in patients with Parkinson’s disease…Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis
Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…Clinical and neurological features of the course of parkinsonism in the presence of chronic renal disease
Objective: To study the clinical and neurological features of the course of parkinsonism in chronic renal disease. Background: Under our supervision were 30 patients with…Blood hexokinase reduction in de novo Parkinson’s disease and remodeling of glycolytic energy homeostasis with L-DOPA/Istradefylline combination therapy
Objective: To evaluate the glycolytic energy homeostasis in Parkinson’s disease (PD), and to define the effects of PD pharmacotherapies on glycolytic dynamics Background: Neuronal energy…Efficacy and safety of istradefylline in Parkinson’s disease patients with postural abnormality: Results from a multicenter, open-label study in Japan
Objective: To investigate the efficacy and safety of istradefylline for the treatment of postural abnormality in patients with Parkinson’s disease (PD). Background: Postural abnormality in…Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis
Objective: To evaluate the Levodopa induced dyskinesia (LID) in the clinical view point of autophagy and cellular energy homeostasis, and the pharmacological effect of adenosine…Efficacy of Istradefylline, an A2A Receptor Antagonist, When Added to Levodopa (LD) and Other Medications for Parkinson’s Disease (PD)
Objective: To evaluate the clinical effect of istradefylline as adjunctive treatment to LD in PD patients with or without additional PD medications (meds). Background: Istradefylline,…Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A2A receptor antagonist
Objective: To evaluate whether an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A receptor antagonist preladenant prevent the onset of…The frequency of lower urinary tract symptoms in patients with Parkinson’s disease and Clinical efficacy of istradefylline
Objective: We evaluated using the questionnaire to investigate the frequency of lower urinary tract symptoms (LUTSs) in Parkinson's disease at our clinic. For patients with…Effect of an Increase in Dose of Istradefylline, an A2A Receptor Antagonist, in Levodopa (LD)-Treated Patients with Parkinson’s Disease (PD)
Objective: To observe whether increasing the istradefylline dose from 20 to 40mg/day provides more patients with meaningful clinical responses. Background: Istradefylline, a well-tolerated selective adenosine…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.